CA2873191A1 - Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity and said ligands - Google Patents

Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity and said ligands Download PDF

Info

Publication number
CA2873191A1
CA2873191A1 CA2873191A CA2873191A CA2873191A1 CA 2873191 A1 CA2873191 A1 CA 2873191A1 CA 2873191 A CA2873191 A CA 2873191A CA 2873191 A CA2873191 A CA 2873191A CA 2873191 A1 CA2873191 A1 CA 2873191A1
Authority
CA
Canada
Prior art keywords
composition
substance
skin
cells
ahr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873191A
Other languages
English (en)
French (fr)
Inventor
Jean Hilaire Saurat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THESAN PHARMACEUTICALS Inc
Original Assignee
THESAN PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THESAN PHARMACEUTICALS Inc filed Critical THESAN PHARMACEUTICALS Inc
Publication of CA2873191A1 publication Critical patent/CA2873191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2873191A 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity and said ligands Abandoned CA2873191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168121.7 2012-05-15
EP12168121.7A EP2664919A1 (fr) 2012-05-15 2012-05-15 Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
PCT/IB2013/053979 WO2013171696A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands

Publications (1)

Publication Number Publication Date
CA2873191A1 true CA2873191A1 (en) 2013-11-21

Family

ID=46801377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873191A Abandoned CA2873191A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity and said ligands

Country Status (19)

Country Link
US (2) US9480674B2 (enExample)
EP (2) EP2664919A1 (enExample)
JP (1) JP6254580B2 (enExample)
KR (1) KR20150022827A (enExample)
CN (1) CN104471391B (enExample)
AU (1) AU2013261093A1 (enExample)
BR (1) BR112014028307A2 (enExample)
CA (1) CA2873191A1 (enExample)
CO (1) CO7240392A2 (enExample)
HK (1) HK1205252A1 (enExample)
IL (1) IL235449A (enExample)
IN (1) IN2014DN10283A (enExample)
MX (1) MX2014013925A (enExample)
NZ (1) NZ702357A (enExample)
PH (1) PH12014502548A1 (enExample)
RU (1) RU2014150505A (enExample)
SG (1) SG11201407405VA (enExample)
WO (1) WO2013171696A1 (enExample)
ZA (1) ZA201408826B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
EP3692999A1 (en) * 2012-03-17 2020-08-12 The Regents of the University of California Fast diagnosis and personalized treatments for acne
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
WO2016022703A1 (en) * 2014-08-06 2016-02-11 Thesan Pharmaceuticals, Inc. Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists
JP2016150916A (ja) * 2015-02-17 2016-08-22 株式会社マンダム 皮脂分泌抑制剤
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN109715179A (zh) 2016-04-21 2019-05-03 内科德生物群系公司 用于治疗皮肤病症的组合物和方法
US11596657B2 (en) 2016-10-04 2023-03-07 Institut National De La Recherche Agronomique Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3875098A1 (en) 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
WO2023064489A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07501540A (ja) * 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び／又は皮膚萎縮を調節するための組成物
BR9908870A (pt) * 1998-03-16 2000-11-21 Procter & Gamble Processos para regularizarem a aparência da pele
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
FR2849597B1 (fr) * 2003-01-08 2006-12-08 Oreal Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives
CA2593140C (en) * 2005-01-05 2013-08-13 Oliver Yoa-Pu Hu Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b)
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
US20060210524A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin care composition
DE102005056890A1 (de) 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
KR100798252B1 (ko) * 2006-01-18 2008-01-24 주식회사 엘지생활건강 ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물
DE102006011747A1 (de) * 2006-03-13 2007-09-27 Symrise Gmbh & Co. Kg Dermatologische und/oder kosmetische Zubereitungen
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
US20090208432A1 (en) 2006-05-03 2009-08-20 Symrise Gmbh & Co., Kg AH Receptor Antagonists
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
KR20110139397A (ko) * 2010-06-23 2011-12-29 건국대학교 산학협력단 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물
CN101953838A (zh) * 2010-08-13 2011-01-26 李岱 吴茱萸次碱用于治疗银屑病的应用
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique

Also Published As

Publication number Publication date
PH12014502548A1 (en) 2015-01-21
JP6254580B2 (ja) 2017-12-27
EP2664919A1 (fr) 2013-11-20
HK1205252A1 (en) 2015-12-11
IL235449A (en) 2017-07-31
BR112014028307A2 (pt) 2017-07-18
JP2015523553A (ja) 2015-08-13
MX2014013925A (es) 2015-05-11
KR20150022827A (ko) 2015-03-04
EP2850429A1 (en) 2015-03-25
ZA201408826B (en) 2016-09-28
CO7240392A2 (es) 2015-04-17
SG11201407405VA (en) 2014-12-30
CN104471391A (zh) 2015-03-25
RU2014150505A (ru) 2016-07-10
NZ702357A (en) 2016-10-28
IN2014DN10283A (enExample) 2015-08-07
AU2013261093A1 (en) 2014-12-18
CN104471391B (zh) 2016-12-07
US20170042856A1 (en) 2017-02-16
US9480674B2 (en) 2016-11-01
WO2013171696A1 (en) 2013-11-21
US20150057343A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
CA2873191A1 (en) Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity and said ligands
Kutlu et al. Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment
Baswan et al. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases
Starace et al. Erosive pustular dermatosis of the scalp: clinical, trichoscopic, and histopathologic features of 20 cases
CN1230169C (zh) 环杷明在银屑病治疗中的应用
Saraswat et al. A randomized, double‐blind, vehicle‐controlled study of a novel liposomal dithranol formulation in psoriasis
US20130102572A1 (en) Methods of treating skin conditions exhibiting telangiectasia
Tuo et al. ALA-PDT suppressing the cell growth and reducing the lipogenesis in human SZ95 sebocytes by mTOR signaling pathway in vitro
Bizikova et al. Effect of a novel topical diester glucocorticoid spray on immediate‐and late‐phase cutaneous allergic reactions in Maltese–beagle atopic dogs: a placebo‐controlled study
Ianhez et al. A randomized, open, controlled trial of tretinoin 0.05% cream vs. low‐dose oral isotretinoin for the treatment of field cancerization
JP5112328B2 (ja) 重度の皮膚科障害の局所的処置のための４−オキソ（イソ）トレチノイン
JPH11502513A (ja) 糖尿病性ニューロパシーの処置方法
Musa et al. Novel topical nano-colloidal carrier loaded with cyclosporine: Biological evaluation potentially for psoriasis treatment
McLaughlin et al. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats
Darmaputra et al. Successful alopecia universalis treatment with the combination of cyclosporine and oral corticosteroid: a case report
US9566262B2 (en) Itch suppression by fucoxanthin
Huynh et al. Effects of Exosomes From Hypoxia-Induced Adipose-Derived Stem Cells on Ameliorating Photoaging
US20250134803A1 (en) Topical dim compositions and uses thereof
Marko et al. Real-life efficiency and safety comparison study of emollient ointment based on glycerophosphoinositol (GPI) salt of choline and other emollient products in patients with atopic dermatitis
Souto-Silva et al. Ibrutinib-loaded lipid nanocarriers exhibit antitumor effect in a human ex vivo skin model of melanoma
US20190209472A1 (en) Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
Sulaiman et al. Evaluation of serum vitamin D3 before and after intralesional vitamin d3 in patients with alopecia areata
Dias et al. Scalp Pruritus
Molesini et al. Influences of the vehicle in the spreading and release of betamethasone
WO2016022703A1 (en) Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190515